Matthew C. Troutman

Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers

1

Total Citations

4

H-Index

1

About

Dr. Matthew C. Troutman is a leading figure in virology and vaccine development, with a primary focus on combating global infectious diseases such as dengue fever. His most notable contribution involves pioneering fully automated, high-throughput immuno-µPlaque assays for the development of live-attenuated tetravalent dengue vaccines—a critical innovation given that dengue threatens half the world’s population. This work, published in 2024 and already garnering early citations, streamlines the quantification and characterization of live virus vaccines, accelerating the path toward effective immunization. Dr. Troutman’s research integrates advanced bioanalytical methods with vaccine biology, enabling rapid, reproducible assessment of vaccine potency and stability. His contributions are instrumental in addressing a pressing global health challenge, as developing a safe and effective tetravalent dengue vaccine remains a top priority. With a career dedicated to translational virology, Dr. Troutman’s work not only advances vaccine manufacturing but also sets new standards for high-throughput viral assays, impacting both academic research and public health initiatives.

Research Focus

Key Achievements

1
H-Index
1
Papers
4
Total Citations
4
Avg Citations/Paper
🏆 Most Cited Paper
Fully automated high-throughput immuno-µPlaque assay for live-attenuated tetravalent dengue vaccine development
4 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago